Navigation Links
Endoscopic ultrasound highly accurate in evaluating ambiguous radiographic findings of the pancreas
Date:8/27/2008

OAK BROOK, Ill. August 27, 2008 Researchers from St. Louis University School of Medicine in Missouri report that EUS and EUS-FNA is 99.1 percent accurate in diagnosing pancreatic neoplasms (abnormal growths or tumors) in patients who were referred for endoscopic ultrasound (EUS) because of CT and/or MRI reports of two common, though somewhat ambiguous findings - enlargement of head of pancreas (HOP) or dilation of the pancreatic duct (PD). The study appears in the August issue of GIE: Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy (ASGE).

Occasionally, patients who are asymptomatic or who have nonspecific symptoms, such as weight loss and abdominal pain, have subtle abnormal or incidental findings on CT and/or MRI that raise suspicion for pancreatic cancer. These tests have relatively low specificity (ability to definitively discern between various diagnoses) in this setting. Perhaps due to a concern of missing early, small pancreatic cancers, physicians who perform EUS are increasingly referred patients with subtle CT or MRI findings such as ''enlarged pancreatic head" or ''dilation of the pancreatic duct (widening of the main duct coursing through the pancreas)." Endoscopic ultrasound and endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) have become a valuable tool in the diagnostic evaluation of patients with suspected pancreatic cancer. This technique allows for detection and possible needle biopsy of small pancreatic tumors even before they can be visualized as a discrete mass with CT or MRI. According to the American Cancer Society, deaths from pancreatic cancer in 2008 are estimated to be approximately 34,000.

"Often, patients with these radiologic findings are referred for EUS in lieu of waiting for repeated imaging. Our study looked to determine the performance characteristics of EUS and/or EUS with FNA in diagnosing a pancreatic tumor in this patient population," said study lead author Banke Agarwal, MD, Saint Louis University School of Medicine. "We found that EUS and/or an EUS-FNA for diagnosing a pancreatic neoplasm was 99.1 percent accurate with 88.8 percent sensitivity and 100 percent specificity."

Endoscopic ultrasound consists of a flexible endoscope which has a small ultrasound device built into the end. The ultrasound component produces sound waves that create visual images of the digestive tract which extend beyond the inner surface lining. EUS can be used to evaluate an abnormality below the surface such as a growth that was detected at a prior endoscopy or by X-ray. EUS can also be used to diagnose diseases of the pancreas, bile duct, and gallbladder when other tests are inconclusive, and can be used to determine the stage of cancers. Tissue samples, using a fine needle aspiration technique (FNA), can be obtained in real time with EUS guidance should an abnormality be seen.

Patients and Methods

This study was a retrospective analysis of 110 patients, mean age 60.3 years, from a prospectively maintained database of patients who underwent an EUS and/or EUS-FNA at St. Louis University Hospital between March 2002 and March 2006 for suspected pancreatic cancer based on an abnormal CT and/or MRI who were reported as having an enlarged HOP or dilation of the PD (with or without a dilated common bile duct). An EUS examination was initially performed by using a radial echoendoscope. Whenever a suspicious "mass" was identified on radial EUS, an FNA was performed using a linear echoendoscope. Fine needle aspirates were submitted for cytology and biochemical analysis. A final diagnosis was based on definitive cytology, surgical pathology or clinical follow up of 12 months or more (median follow up was 16 months).

Results

Researchers found that 6 percent of patients referred because of an enlarged HOP on a CT and/or an MRI and 11.5 percent of patients referred for a dilated PD had a pancreatic neoplasm. The diagnostic accuracy of an EUS and/or EUS-FNA in these patients for diagnosing a pancreatic neoplasm was 99.1 percent. Furthermore, no patient with enlarged HOP, but without a mass at EUS, went on to develop cancer.

In conclusion, researchers found that a pancreatic neoplasm is present in a clinically significant number of patients with an ''enlarged HOP'' or "dilated PD" detected on a CT and/or MRI performed for evaluation of nonspecific symptoms, such as abdominal pain or weight loss. They also observed that an EUS and/or EUS-FNA are highly accurate for the diagnosis of pancreatic neoplasm in these patients. Based on these data, researchers recommend that an EUS and/or EUS-FNA be considered as the logical next test in the evaluation of patients with such imaging findings.


'/>"/>

Contact: Anne Brownsey
abrownsey@asge.org
630-570-5635
American Society for Gastrointestinal Endoscopy
Source:Eurekalert

Related medicine news :

1. Endoscopic circumferential ablation promising for Barretts esophagus with high-grade dysplasia
2. Portable Endoscopic Company Announces Hiring of David Guy as COO/President
3. How to use endoscopic stent for biliary stricture trauma?
4. joimax(R) Revolutionizes Spine Surgery With the Launch of Newest and Fully-Endoscopic Product Innovations to Treat Spinal Canal Stenosis
5. ASGE offers guidelines on endoscopic treatment of dyspepsia
6. Endoscopic resection is a safe and effective treatment for gastrointestinal smooth muscle tumors
7. First Major Medical Meeting Convening for MRI-guided Focused Ultrasound to Treat Cancer, Stroke, Fibroids, Other Conditions
8. Ultrasound used to predict heart attack risk
9. Heel Ultrasound Helps Detect Fracture Risk
10. Accuracy of ultrasound screening in pregnancy: Effects of examiner and device quality unclear
11. Simple ultrasound exam may predict osteoporosis risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology: